Daewoong Pharmaceutical Appoints Park Seong-soo as New CEO to Lead Global Expansion and R&D
Park Seong-soo, the new CEO of Daewoong Pharmaceutical / Photo = Daewoong Pharmaceutical Daewoong Pharmaceutical (CEOs Chang-jae Lee and Seong-soo Park) announced on the 29th that they are holding a board of directors meeting on the 28th and have decided to appoint a new CEO Park Seong-soo. Daewoong Pharmaceutical operates a dual CEO system, with […]
Daewoong Pharmaceutical Recognized as a Best Company to Work For at GPTW 2024 Strategy Inception Conference
Daewoong Pharmaceutical Showcases Exemplary Corporate Culture at GPTW 2024 Strategy Inception Conference Daewoong Pharmaceutical, led by CEOs Chang-jae Lee and Seung-ho Jeon, made a significant announcement on the 20th regarding its participation in the GPTW 2024 Strategy Inception Conference. The company disclosed valuable insights at the event, which was organized by ‘Great Place to Work’ […]
Daewoong Pharmaceutical’s Enblo Receives Approval from Major Hospitals for Diabetes Inhibitor Drug
Daewoong Pharmaceutical’s SGLT-2 diabetes inhibitor drug, Enblo (ingredient: inavogliflozin), has recently been granted approval from several major general hospitals, including Samsung Seoul Hospital, University Hospital Seoul National, Asan Medical Center, and Resignation Hospital. This announcement comes after Enblo successfully passed the Pharmaceutical Affairs Committee of approximately 40 hospitals, including renowned university and general hospitals, just […]
